RESEARCH FRONTIERS INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that RESEARCH FRONTIERS INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $381.5K | Mar 12, 2020 |
| FY2019 | Sep 30, 2019 | $462.9K | Mar 12, 2020 |
| FY2019 | Jun 30, 2019 | $301.0K | Mar 12, 2020 |
| FY2019 | Mar 31, 2019 | $418.7K | Mar 12, 2020 |
| FY2019 | Dec 31, 2018 | $370.8K | Mar 12, 2020 |
| FY2019 | Sep 30, 2018 | $359.7K | Mar 12, 2020 |
| FY2019 | Jun 30, 2018 | $324.9K | Mar 12, 2020 |
| FY2019 | Mar 31, 2018 | $433.3K | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $279.4K | Mar 14, 2019 |
| FY2018 | Sep 30, 2017 | $488.3K | Mar 14, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.12M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $1.34M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $909.6K | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $539.7K | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $1.26M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $828.5K | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | $1.56M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $1.49M | Mar 12, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.05M) | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | ($1.31M) | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | ($1.91M) | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | ($2.67M) | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | ($1.85M) | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | ($2.34M) | Mar 9, 2022 |
| FY2019 | Dec 31, 2019 | ($1.26M) | Mar 12, 2020 |
| FY2019 | Sep 30, 2019 | ($397.7K) | Mar 12, 2020 |
| FY2019 | Jun 30, 2019 | ($1.35M) | Mar 12, 2020 |
| FY2019 | Mar 31, 2019 | ($803.9K) | Mar 12, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.13M) | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | ($1.44M) | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | ($2.03M) | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | ($2.63M) | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | ($1.84M) | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | ($2.58M) | Mar 9, 2022 |
| FY2019 | Dec 31, 2019 | ($1.27M) | Mar 12, 2020 |
| FY2019 | Sep 30, 2019 | ($410.9K) | Mar 12, 2020 |
| FY2019 | Jun 30, 2019 | ($952.3K) | Mar 12, 2020 |
| FY2019 | Mar 31, 2019 | ($562.5K) | Mar 12, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $608.7K | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $570.0K | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $583.3K | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $609.1K | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $580.0K | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $628.3K | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | $1.04M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $863.4K | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $799.7K | Mar 14, 2019 |
| FY2018 | Dec 31, 2016 | $1.42M | Mar 14, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.33M) | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | ($788.8K) | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | ($2.30M) | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | ($2.18M) | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | ($1.80M) | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | ($2.25M) | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | ($2.08M) | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | ($2.07M) | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | ($1.47M) | Mar 14, 2019 |
| FY2018 | Dec 31, 2016 | ($4.01M) | Mar 14, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $726 | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $1.6K | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $1.6K | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $1.3K | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $1.1K | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $56.5K | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | $65.3K | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $11.7K | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $6.5K | Mar 14, 2019 |
| FY2018 | Dec 31, 2016 | $11.7K | Mar 14, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.25M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $4.04M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $3.85M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $5.37M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $4.55M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $6.20M | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | $8.26M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $4.06M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $2.88M | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | $5.27M | Mar 13, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.32M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $1.44M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $332.8K | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $569.6K | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $762.1K | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $872.3K | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | $1.20M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $959.1K | Mar 12, 2020 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $933.6K | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $2.60M | Mar 5, 2026 |
| FY2025 | Dec 31, 2023 | $3.52M | Mar 5, 2026 |
| FY2024 | Dec 31, 2022 | $4.80M | Mar 6, 2025 |
| FY2023 | Dec 31, 2021 | $3.78M | Mar 7, 2024 |
| FY2022 | Dec 31, 2020 | $5.33M | Mar 9, 2023 |
| FY2021 | Dec 31, 2019 | $7.06M | Mar 9, 2022 |
| FY2020 | Dec 31, 2018 | $3.10M | Mar 11, 2021 |
| FY2019 | Dec 31, 2017 | $2.57M | Mar 12, 2020 |
| FY2018 | Dec 31, 2016 | $4.90M | Mar 14, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($127.62M) | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | ($125.58M) | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | ($124.26M) | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | ($122.36M) | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | ($119.69M) | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | ($117.84M) | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | ($115.50M) | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | ($111.69M) | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | ($109.06M) | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | ($106.65M) | Mar 13, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $664.3K | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $1.99M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $2.48M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $4.23M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $270.0K | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $4.77M | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | $6.59M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $2.97M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $1.74M | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | $1.69M | Mar 13, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 9, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 7, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 33.65M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | 33.65M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | 33.51M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | 33.15M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | 31.65M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | 31.58M | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | 31.25M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | 27.67M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | 24.04M | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | 24.04M | Mar 13, 2018 |